Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Blood Cancer J. 2021 Jul 2;11(7):125. doi: 10.1038/s41408-021-00516-1.

Authors

Ibrahim Aldoss¹, Raju Pillai², Dongyun Yang³, Lixin Yang², Shukaib Arslan⁴, Sally Mokhtari⁴, Monzr M Al Malki⁴, Amandeep Salhotra⁴, Shilpa Shahani⁵, Haris Ali⁴, Matthew Mei⁴, Andrew Artz⁴, David Snyder⁴, Michelle Afkhami², Saro Armenian⁵, Anthony Stein⁴, Guido Marcucci⁴, Stephen J Forman⁴, Ryotaro Nakamura^#⁴, Vinod Pullarkat^#⁴

Affiliations

¹ Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA. ialdoss@coh.org.
² Department of Pathology, City of Hope, Duarte, CA, USA.
³ Department of Computational and Quantitative Medicine, City of Hope, Duarte, CA, USA.
⁴ Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
⁵ Department of Pediatrics, City of Hope, Duarte, CA, USA.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Adolescent
Adult
Child
Child, Preschool
Disease Management
Female
Follow-Up Studies
Humans
Male
Neoplasm Recurrence, Local / diagnosis
Neoplasm Recurrence, Local / etiology*
Neoplasm Recurrence, Local / therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
Survival Analysis
Treatment Outcome
Young Adult

Grants and funding

P30 CA033572/CA/NCI NIH HHS/United States